Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment-Reference-Cited by-同舟云学术

Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment

Published:2017-12 Issue:3 Volume:47 Page:323-330
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Roemer Frank W.,Miller Colin G.,West Christine R.,Brown Mark T.,Sherlock Sarah P.,Kompel Andrew J.,Diaz Luis,Galante Nicholas,Crema Michel D.,Guermazi Ali

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference38 articles.

1. Tanezumab for the treatment of pain from osteoarthritis of the knee;Lane;N Engl J Med,2010

2. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain;Schnitzer;Ann Rheum Dis,2015

3. Nerve growth factor: an update on the science and therapy;Seidel;Osteoarthritis Cartilage,2013

4. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies;Hochberg;Osteoarthritis Cartilage,2015

5. When is osteonecrosis not osteonecrosis? adjudication of reported serious adverse joint events in the tanezumab clinical development program;Hochberg;Arthritis Rheumatol,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab;Osteoarthritis and Cartilage;2023-12

2. Role of imaging for eligibility and safety of a-NGF clinical trials;Therapeutic Advances in Musculoskeletal Disease;2023-01

3. Inter-reader consistency and exclusionary findings during radiographic screening for Phase 3 trials of tanezumab in patients with osteoarthritis;Osteoarthritis Imaging;2022-09

4. Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review;BioDrugs;2021-11

5. Long‐Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial;Arthritis & Rheumatology;2021-06-07